Scientists have shown in mice that skin cells re-programmed into brain stem cells, transplanted into the central nervous system, help reduce inflammation and may be able to help repair damage caused by multiple sclerosis (MS).
Our mouse study suggests that using a patient’s reprogrammed cells could provide a route to personalised treatment of chronic inflammatory diseases, including progressive forms of MS
The study, led by researchers at the University of Cambridge, is a step towards developing personalised treatments based on a patient’s own skin cells for diseases of the central nervous system (CNS).
In MS, the body’s own immune system attacks and damages myelin, the protective sheath around nerve fibres, causing disruption to messages sent around the brain and spinal cord. Symptoms are unpredictable and include problems with mobility and balance, pain, and severe fatigue.
Key immune cells involved in causing this damage are macrophages (literally ‘big eaters’), which ordinarily serve to attack and rid the body of unwanted intruders. A particular type of macrophage known as microglia are found throughout the brain and spinal cord – in progressive forms of MS, they attack the CNS, causing chronic inflammation and damage to nerve cells.
Recent advances have raised expectations that diseases of the CNS may be improved by the use of stem cell therapies. Stem cells are the body’s ‘master cells’, which can develop into almost any type of cell within the body. Previous work from the Cambridge team has shown that transplanting neural stem cells (NSCs) – stem cells that are part-way to developing into nerve cells – reduces inflammation and can help the injured CNS heal.
However, even if such a therapy could be developed, it would be hindered by the fact that such NSCs are sourced from embryos and therefore cannot be obtained in large enough quantities. Also, there is a risk that the body will see them as an alien invader, triggering an immune response to destroy them.
A possible solution to this problem would be the use of so-called ‘induced neural stem cells (iNSCs)’ – these cells can be generated by taking an adult’s skin cells and ‘re-programming’ them back to become neural stem cells. As these iNSCs would be the patient’s own, they are less likely to trigger an immune response.
Now, in research published in the journal Cell Stem Cell, researchers at the University of Cambridge have shown that iNSCs may be a viable option to repairing some of the damage caused by MS.
Using mice that had been manipulated to develop MS, the researchers discovered that chronic MS leads to significantly increased levels of succinate, a small metabolite that sends signals to macrophages and microglia, tricking them into causing inflammation, but only in cerebrospinal fluid, not in the peripheral blood.
Transplanting NSCs and iNSCs directly into the cerebrospinal fluid reduces the amount of succinate, reprogramming the macrophages and microglia – in essence, turning ‘bad’ immune cells ‘good’. This leads to a decrease in inflammation and subsequent secondary damage to the brain and spinal cord.
“Our mouse study suggests that using a patient’s reprogrammed cells could provide a route to personalised treatment of chronic inflammatory diseases, including progressive forms of MS,” says Dr Stefano Pluchino, lead author of the study from the Department of Clinical Neurosciences at the University of Cambridge.
“This is particularly promising as these cells should be more readily obtainable than conventional neural stem cells and would not carry the risk of an adverse immune response.”
The research team was led by Dr Pluchino, together with Dr Christian Frezza from the MRC Cancer Unit at the University of Cambridge, and brought together researchers from several university departments.
Dr Luca Peruzzotti-Jametti, the first author of the study and a Wellcome Trust Research Training Fellow, says: “We made this discovery by bringing together researchers from diverse fields including regenerative medicine, cancer, mitochondrial biology, inflammation and stroke and cellular reprogramming. Without this multidisciplinary collaboration, many of these insights would not have been possible.”
The Latest on: Personalised stem cell treatment
- Genentech’s personalized medicine entrectinib gets US FDA priority review designation on February 19, 2019 at 9:30 pm
Genentech, announced that the US Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult ... i... […]
- Roche's personalised medicine, entrectinib receives US FDA priority review status on February 19, 2019 at 7:30 pm
"By combining comprehensive genomic profiling with actionable targeted therapies, like entrectinib, we are advancing our personalised healthcare goal to find the right treatment for each ... result in ... […]
- Progress in the treatment of aggressive brain tumors on February 19, 2019 at 6:51 am
The drug alters the DNA in the cancer cells, which die as a result ... "This is a tailor-made therapy for this subgroup," emphasizes Herrlinger. "Ultimately, this is an initial step toward personalize... […]
- FDA grants Priority Review to Roche's personalised medicine entrectinib on February 19, 2019 at 3:47 am
"Entrectinib represents a unique approach to cancer treatment that can potentially ... which plays a role in controlling how cells grow and proliferate. When a ROS1 gene fusion occurs, cancer ... […]
- CMS looks to expand Medicare coverage to CAR-T therapy on February 15, 2019 at 1:59 pm
In CAR T-cell therapy, a patient’s white blood cells are extracted and modified with a receptor ... Bens, senior vice president for public policy at the Personalized Medicine Coalition, said in a stat... […]
- ISABS: Personalized Medicine Conference With Nobel Laureates to Be Held in Split, Croatia on February 15, 2019 at 9:24 am
The Conference is supported by The American Academy for Forensic Sciences and conference topics include: personalized and regenerative medicine, pharmacogenomics, molecular diagnostics, stem cell ther... […]
- Innovative Treatments May Require Equally Innovative Health Care Payment Models on February 13, 2019 at 9:01 pm
For instance, advancements in gene therapy and personalized treatments could one ... marvel of modern science that reengineers a person's cells so that they attack cancer cells, but a one-time ... […]
- Korean biotechs snatch U.S. stem cell manufacturing facility on February 13, 2019 at 9:00 am
Argos had its stock delisted and essentially closed up shop last year after its dendritic cell-based personalized kidney ... a production facility for cGMP cell therapy in the U.S. and produce a high- ... […]
- New Oxford-developed tool reads the life histories of cancer cells on February 12, 2019 at 6:14 pm
which may lead to more effective and personalized cancer treatments. Cancer cells are basically just normal cells that have accumulated certain mutations that allow them to grow out of control. […]
- AIVITA Identifies Mechanism to Enhance Patient Response Rate to Next Generation Cancer Stem Cell Immunotherapy on February 12, 2019 at 11:00 am
The biomarker can be used to predict immune response to AIVITA's personalized cancer immunotherapy ... 55 patients to receive the cancer stem cell-targeting immunotherapy. Patients eligible for treatm... […]
via Google News and Bing News